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Combinations of cisplatin–irinotecan and cisplatin–etoposide are active and well tolerated in patients with both small-cell lung
cancer (SCLC) and nonsmall-cell lung cancer (NSCLC). To define the recommended dose for phase II trials of irinotecan combined
with cisplatin and etoposide in chemonaive patients with stage IV disease, 56 patients (11 having SCLC and 45 NSCLC) received
cisplatin 25mgm
2 weekly for 9 weeks, etoposide 60mgm
2 for 3 days on weeks 1, 3, 5, 7 and 9, and irinotecan 20–100mgm
2
(levels 1–8) on weeks 2, 4, 6 and 8, together with a prophylactical granulocyte colony-stimulating factor support (50mgm
2 on days
4–7 on weeks 1, 3, 5, 7 and 9, and on days 2–7 on weeks 2, 4, 6 and 8). Grade 3–4 leukocytopenia, neutropenia and
thrombocytopenia were noted in 20 (36%), 28 (50%) and nine (16%) patients, respectively. Grade 3 diarrhoea, grade 3 cardiac
toxicity, and grade 4 transaminase elevation developed in one (1.8%) patient each. Totally, four of 56 patients were removed from
the study because of toxicity and recovered, and two other patients died in situations where drug toxicity might contribute to their
death. Dose-limiting toxicity was noted in less than one-third of patients at dose levels 1–7, but in all patients at dose level 8. Thus,
the recommended dose was determined to be level 7 (irinotecan 90mgm
2). The response rates for SCLC and NSCLC were 91%
(10/11) and 38% (17/45), respectively. The median survival time and 1-year survival rate were 11.9 months and 46% for SCLC and
10.1 months and 40% for NSCLC, respectively. This regimen was considered to be feasible and promising for the treatment of stage
IV SCLC and NSCLC.
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The combination of cisplatin and etoposide has been the standard
chemotherapeutic regimen for small-cell lung cancer (SCLC) and
was one of the frequently used regimens in the treatment of
nonsmall-cell lung cancer (NSCLC) (Ardizzoni et al, 1999; Murren
et al, 2001). This drug combination has a relatively mild toxicity
profile, enabling other cytotoxic agents or thoracic radiotherapy to
be added to this regimen (Loehrer et al, 1995; Turrisi et al, 1999).
Irinotecan, a camptothecin derivative topoisomerase I inhibitor,
has been shown to exhibit excellent antitumour activity against
SCLC and NSCLC in monotherapy and in combination with
cisplatin (Fukuoka et al, 1992, 2000; Masuda et al, 1992; Noda
et al, 2002). Thus, addition of irinotecan to the cisplatin and
etoposide regimen may improve the efficacy against advanced lung
cancer.
Weekly chemotherapy regimens have been developed to
incorporate multiple drugs into one regimen, to obtain the optimal
schedule of each drug, or to increase the dose intensity of cytotoxic
agents. A CODE regimen, in which cisplatin, etoposide, doxor-
ubicin and vincristine are administered on a weekly basis for nine
cycles, has produced high response rates for both SCLC (85%) and
NSCLC (62%) (Murray et al, 1991, 1999). A randomised trial of this
regimen with and without granulocyte colony-stimulating factor
(G-CSF) showed that the addition of G-CSF increased the actual
dose intensity of all drugs with a significant improvement in
survival (Fukuoka et al, 1997). We showed the CODE regimen with
the G-CSF support to be highly effective aganist extensive SCLC
and relapsed SCLC (Kubota et al, 1997; Furuse et al, 1998). Thus,
although toxicity of the original CODE regimen was greater than
that of the standard regimen (Murray et al, 1999), the CODE
regimen with the G-CSF support is thought to be promising for the
treatment of SCLC.
The CODE regimen, in spite of the addition of doxorubicin and
vincristine, keeps the dose intensity of cisplatin and etoposide at
levels that are comparable to those used in the standard cisplatin
and etoposide regimen, which is repeated every 3 weeks (Figure 1).
Thus, it is reasonable to assume that weekly cisplatin and
etoposide can be safely combined with another cytotoxic agent
by replacing the doxorubicin and vincristine in the CODE regimen
with the third agent. Furthermore, this weekly schedule may be of
great advantage to obtain synergistic effects of etoposide
(topoisomerase II inhibitor) and irinotecan, because the
development of resistance to topoisomerase II inhibitors was
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lreported to increase tumour sensitivity to subsequent treatment
with topoisomerase I inhibitors (Vasey and Kaye, 1997).
The objectives of this study were: (1) to establish the maximum
tolerated dose (MTD) and recommended dose for phase II trials of
irinotecan combined with weekly cisplatin and etoposide treat-
metns, and (2) to observe the antitumour activity of this regimen
in patients with SCLC and NSCLC.
PATIENTS AND METHODS
Patient selection
Patients were enrolled in the study if they met the following
criteria: (1) a histologic or cytologic diagnosis of lung cancer; (2)
metastatic disease (stage IV); (3) age of 70 years or younger; (4)
predicted life expectancy of 12 weeks or longer; (5) performance
status of 0 or 1 on the Eastern Cooperative Oncology Group
(ECOG) scale; (6) no prior chemotherapy; (7) no prior radio-
therapy to the primary site; (8) adequate organ function as
documented by a WBC count X4.010
9l
1, haemoglobin
X9.0gdl
1, platelet count X10010
9l
1, total serum bilirubin
p1.5mgdl
1, hepatic transaminases 2the normal institutional
upper limit of normal or lower, serum creatinine p1.5mgdl
1;
and (9) written informed consent.
Patients were not eligible for the study if they had experienced
any of the following events: (1) pleural effusion requiring drainage;
(2) prior radiotherapy with an irradiated area larger than one-third
of the bone marrow volume; (3) synchronous active malignancies
other than multiple lung cancers; (4) active infection; (5) contra-
indications for the use of irinotecan, including diarrhoea, ileus,
interstitial pneumonitis, lung fibrosis or massive ascites; (6)
serious concomitant medical illness, including severe heart
disease, uncontrollable diabetes mellitus or hypertension; or (7)
pregnancy or lactation.
Pretreatment evaluation
Pretreatment assessment included a complete blood cell count,
differential counts, routine chemistry measurements, creatinine
clearance, blood gas analysis, electrocardiogram, lung function
test, chest X-rays, chest conventional tomography, chest computed
tomographic (CT) scan, brain CT scan or magnetic resonance
imaging, abdominal CT scan or ultrasound sonography, radio-
nuclide bone scan, bone X-rays if indicated, and bronchoscopy.
Treatment schedule
All therapy was given on an in-patient basis. Cisplatin (25mgm
2)
was administered intravenously (i.v.) over 60min on day 1 and at
1-week intervals for 9 weeks; etoposide (60mgm
2) was adminis-
tered i.v. over 60min on days 1–3 of weeks 1, 3, 5, 7 and 9; and
irinotecan was administered i.v. over 90min on day 1 on weeks 2,
4, 6 and 8. The dose levels of irinotecan were 20, 40mgm
2, and
subsequent increments of 10mgm
2 up to 100mgm
2. Hydration
(2000ml) and granisetron (40mgkg
1) were given on day 1,
followed by a 1000ml infusion on days 2–5. Prophylactically, G-
CSF (50mgm
2) was administered on days when the cytotoxic
drugs were not given (on days 4–7 on weeks 1, 3, 5, 7 and 9, and
on days 2–7 on weeks 2, 4, 6 and 8), unless the WBC count
exceeded 10.010
9l
1.
Toxicity assessment and treatment
During the course of treatment, complete blood cell counts and
differential counts were analysed twice a week, and routine
chemistry measurements and a chest X-ray were performed once
a week. Toxicity was graded according to the toxicity criteria of the
Japan Clinical Oncology Group (JCOG) (Tobinai et al, 1993), a
modified version of the NCI common toxicity criteria issued in
1991. Grade 4 neutropenia is defined as o0.510
9l
1 and grade 3
neutropenia is defined as X0.5–o1.010
9l
1 in the JCOG
criteria. The second and subsequent cycles of chemotherapy were
delayed for 1 week if one of the following toxicities was noted on
day 1: a WBC count o2.010
9l
1, a platelet count o7510
9l
1,
a serum creatinine level X2.0mgdl
1, an elevated hepatic
transaminase level or total serum bilirubin of grade 2 or higher,
diarrhoea of grade 1–2, fever X381C, or a performance status of 3.
The treatment was terminated if the above-mentioned criteria did
not disappear in 3 weeks or if one of the following severe
nonhaematological toxicity was noted: diarrhoea of grade 2 lasting
for more than 1 week, diarrhoea of grade 3, neurotoxicity of grade
3, or drug-induced pneumonitis.
Dose-limiting toxicity (DLT), MTD, and recommended
dose for phase II trials
The DLT was defined as grade 4 neutropenia lasting for 4 days or
longer, grade 4 neutropenia associated with infection, grade 4
thrombocytopenia, grade 3 or severer nonhaematological toxicity
other than nausea and vomiting, and the termination of treatment
because of the above criteria before four cycles of treatment had
been completed. Dose escalation was made, in principle, according
to the frequency of DLT in the initial four cycles of the therapy at a
level, but the toxicity of all cycles was referred to in the
determination of the dose level. Six patients were initially enrolled
at each dose level. If one or none of them experienced DLT, then the
next cohort of patients was treated at the next higher dose level. If
two or three of the six patients experienced DLT, then an additional
six patients were enrolled at the same dose level, for a total of 12
patients. If three or fewer of these patients experienced DLT, then
the next cohort of patients was treated at the next higher dose level.
If four or more of the initial six or of the 12 patients experienced
DLT, then that level was considered to be the MTD. The numbers of
patients in the cohorts were set to be approximately twice the
number of patients in standard phase I trials in order to calculate
the median dose intensity for each cohort.
The dose intensity of irinotecan (mgm
2week
1) was calculated
for each patient using the following formula:
Totalmilligramsof irinotecaninallcyclesperbodysurfacearea
Totaldaysof therapy=7
where total days of therapy is the number of days from day 1 of
cycle 1 to day 8 of the last cycle (Longo et al, 1991). The median
dose intensity was then calculated at each dose level. The
Figure 1 Treatment schedule and dose intensity for the standard
cisplatin and etoposide regimen, CODE regimen, and the present study. D
(n): doxorubicin; E (’): etoposide; I ( ): irinotecan; P (K): cisplatin; V
(B): vincristine.
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lrecommended dose of irinotecan for phase II trials was defined as
the dose preceding the MTD. However, the median dose intensity
at the dose level was also taken into consideration when
determining the recommended dose.
Response evaluation
Objective tumour responses were evaluated according to the WHO
criteria issued in 1979 (WHO, 1979). A complete response (CR)
was defined as the disappearance of all known disease for at least 4
weeks with no new lesions appearing. A partial response (PR)
referred to an at least 50% decrease of total tumour size for at least
4 weeks without the appearance of new lesions. No change (NC)
was defined as the absence of a partial or CR, and no progressive
or new lesions were observed for at least 4 weeks. Progressive
disease was defined as a 25% or greater increase in the size of any
measurable lesion or the appearance of new lesions.
The response rate and its 95% confidence interval for all patients
were calculated separately for SCLC and NSCLC in the final
analysis. If the upper limit of the interval exceeded 70% in SCLC
and 30% in NSCLC, then phase II studies were planned for each
tumour type.
Data management and statistical considerations
This study was designed as a phase I/II trial among two
participating centers of the Lung Cancer Study Group in JCOG.
The protocol and consent form were approved by the Clinical Trial
Review Committee of JCOG and the Institutional Review Board of
the National Cancer Center. Patient registration and data manage-
ment were performed by the JCOG Data Center. Interim
monitoring was performed by the JCOG Data Center to ensure
quality control. Monitoring reports were submitted to and
reviewed by the JCOG Data and Safety Monitoring Committee
(DSMC) semiannually. The planned accrual and follow-up periods
were 12 and 24 months, respectively. The duration of overall
survival was measured from the date of registration to the date of
death from any cause or the last follow-up. The survival
distribution was estimated using the Kaplan–Meier method, and
the confidence intervals were based on Greenwoods’ formula
(Armitage and Berry, 1994). The statistical analysis was performed
mostly by the JCOG Data Center using SAS software version 6.12
for Windows (SAS Institute Inc., Cary, NC, USA). The dose
intensity was calculated by the Study Coordinator.
RESULTS
From June 1995 to December 1997, 56 patients were entered in the
study; the last follow-up was performed in December 1999. When
six patients were registered at each dose level, the registration was
suspended to assess the DLT of patients entered at each dose level.
Totally, the registration was closed for 6.6 months. The
demographic details are listed in Table 1. All patients were
chemonaive, and had stage IV disease. Small-cell carcinoma
accounted for 11 (20%) of the 56 patients. One patient enrolled
at dose level 5 was treated with etoposide at an erroneous dose of
100mgm
2 for 3 days during the first cycle and at the correct dose
during subsequent cycles. This was a major protocol violation, but
nine cycles of the treatment were completed without severe toxicity
in this patient. Therapy was terminated because of progressive
disease in four patients, patient refusal because of the lack of
antitumour effect in one patient, toxicity in four patients, and
death in one patient. The last patient received three cycles of the
therapy, developed grade 4 neutropenia for 7 days (DLT) and
leukopenia for 3 days, and died 29 days after the registration of
massive haemoptysis from the tumour, which exhibited a large
reduction in size and cavitation. Another patient who was treated
at dose level 5 developed cardiac tamponade and an elevated
hepatic transaminase level of grade 4 (DLT) as a result of a
congestive liver, and died 15 days after the completion of nine
cycles of the therapy. Cytological analysis of pericardial effusion
was not performed in this patient. No other deaths occurred
during or within 30 days of the therapy.
Treatment delivery and dose intensity
The treatment delivery and dose intensity were evaluated in 51
patients (Table 2). Five patients were excluded from the analysis,
because of the early discontinuation of this therapy as a result of
progressive disease in four patients and a protocol violation in one
patient. At dose levels 1–7, 80% or more of the patients completed
all nine cycles of the therapy, whereas only 50% of the patients at
dose level 8 completed the regimen. The percentages of actual
median dose intensity against projected dose intensity were more
than 80% at dose levels 1–7 but only 71% at dose level 8. The dose
level that produced the highest dose intensity of irinotecan
(34.5mgm
2week
1) was level 7.
Toxicity, MTD, and recommended dose for phase II trials
Severe toxicity was mainly haematological. Grade 3–4 leukopenia,
neutropenia and thrombocytopenia were observed in 20 (36%), 28
(50%), and nine (16%) of the 56 patients, but no febrile
neutropenia was encountered. Grade 3 diarrhoea (DLT) was noted
in only one patient at dose level 6 (Table 3). One patient at dose
level 8 complained of chest pain after the completion of two cycles
of therapy. The patient had a history of angina pectoris and had
undergone a percutaneous transluminal coronary angioplasty 7
months before the cancer treatment. The electrocardiogram during
the attack showed an elevated ST segment at the II, III, and aVF
leads, but the following electrocardiograms were normal. A
coronary artery angiography performed on the same day revealed
no narrowing in the coronary artery, but the administration of
ergotamine induced vasospasm in the artery. A diagnosis of
variant angina was made, and therefore there was possibility that
coronary artery spasm was induced by the administration of
anticancer agents. This was counted as grade 3 cardiac toxicity
(DLT). Nonhaematologic toxicity was mild and transient in all
other patients.
Table 1 Patient characteristics
Median (range) N (%)
Number of patients 56
Gender
Male 41 (73)
Female 15 (27)
Age 58 (38–70)
PS
0 12 (21)
1 44 (79)
Body weight loss
0% 38 (68)
1–9% 14 (25)
X10% 4 (7)
Histology
Small-cell carcinoma 11 (20)
Adenocarcinoma 35 (63)
Squamous-cell carcinoma 5 (9)
Large-cell carcinoma 4 (7)
Others 1 (2)
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lDLT occurred in less than one-third of patients treated at dose
levels 1–7, whereas DLT developed within four cycles of therapy in
two patients treated at dose level 8, and within nine cycles in all
patients treated at this level (Table 4). Thus, the MTD was
determined to be dose level 8. In consideration of the good
treatment delivery and the highest dose intensity achieved at dose
level 7, the recommended dose for the phase II trials was
established to be dose level 7, or 90mgm
2 of irinotecan, for this
schedule.
Objective responses and survival
All the patients were included in the analyses of tumour response
and survival. The response rate (95% confidence interval) was 91%
(59–100%) in 11 patients with SCLC and 38% (24–54%) in 45
patients with NSCLC (Table 5). The response rate in the 23 NSCLC
patients registered at dose levels 1–5 was 39%, while that in the 22
NSCLC patients registered at dose levels 6–8 was 36%. The median
survival time (95% confidence interval) and 1-year survival rate
(95% confidence interval) were 11.9 (9.7–15.6) months and 46%
(16–75%) in the 11 patients with SCLC and 10.1 (7.8–12.3)
months and 40% (26–54%) in the 45 patients with NSCLC,
respectively.
DISCUSSION
This study established the recommended dose of irinotecan
(90mgm
2 biweekly) for phase II studies in combination
with weekly cisplatin (25mgm
2 weekly) and etoposide
(60mgm
2 for 3 days biweekly) treatments and a G-CSF support.
At this dose level, nine weekly consecutive administrations of
chemotherapy were completed in more than 80% of patients, and
the highest dose intensity was obtained. The cumulative doses of
cisplatin and irinotecan at their recommended doses, 225 and
360mgm
2, respectively, corresponded to 94 and 50%, respec-
tively, of those in the standard cisplatin and irinotecan regimen,
which is repeated every 4 weeks for a total of four cycles. The dose
intensity of irinotecan, however, was 86% of that in the standard
regimen (Noda et al, 2002). The cumulative dose of etoposide is
75% of that in the standard cisplatin and etoposide regimen
Table 2 Treatment delivery and dose intensity (N=51)
Dose of
No. of patients
Median dose intensity
(mgm
2week
1)
Level
irinotecan
(mgm
2) Evaluated
Completed
nine cycles (%) Projected Actual (%)
1 20 6 5 83 8.6 8.6 99
2 40 6 6 100 17.2 17.2 100
3 50 5 5 100 21.6 21.5 100
4 60 5 4 80 25.9 21.3 82
5 70 6 6 100 30.2 27.2 90
6 80 12 10 83 34.5 32.8 95
7 90 7 7 100 38.8 34.5 89
8 100 4 2 50 43.1 30.4 71
Five patients were excluded from this analysis because of progressive disease in four patients and protocol violation in one
patient.
Table 3 Toxicity evaluated for all cycles (N=56)
Grade Absent 1 2 3 4
Anaemia 0 2 19 29 F
Leukocytopenia 0 13 18 17 3
Neutropenia 0 5 15 17 11
Thrombocytopenia 0 5 11 8 1
Elevated total bilirubin 0 F 14 0 0
Elevated GOT 0 16 0 1 0
Elevated GPT 0 27 3 0 1
Elevated creatinine 0 6 3 0 0
Hyponatremia 0 21 6 1 0
Hypokalemia 0 10 2 1 0
Infection 0 8 6 0 0
Nausea/vomiting 1 26 19 4 F
Diarrhoea 0 21 6 1 0
Stomatitis 1 6 1 0 0
Alopecia 2 37 13 0 F
Table 4 Dose-limiting toxicity by dose levels (N=56)
No. of pts with DLT within
Level Total no. of pts Four cycles All cycles Type of DLT (no. of pts)
1 6 0 0 None
2 6 0 0 None
3 7 0 0 None
4 6 1 1 Neutropenia+hyponatremia (1)
5 7 0 2 Neutropenia+hypokalemia (1), elevated hepatic transaminases (1)
6 13 2 4 Neutropenia (2), thrombocytopenia (1), diarrhoea (1)
7 7 0 1 Neutropenia (1)
8 4 2 4 Neutropenia (3), cardiac ischaemia (1)
DLT: dose-limiting toxicity; pts: patients.
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lrepeated every 3 weeks for a total of four cycles, but the dose
intensity of etoposide is the same as that in the standard regimen
(Noda et al, 2002). Thus, although the cumulative doses of
irinotecan and etoposide are less than those for the standard
regimens, the dose intensity of each drug is well maintained and
comparable to those of the standard regimens.
Some of the criteria in this study’s protocol were determined
arbitrarily because of the lack of published reports on dose
findings for weekly chemotherapy regimens. First, the decision to
escalate the dose was made when the toxicity and DLT data for the
initial four cycles of therapy had been collected. This protocol was
adopted because (1) DLT is generally assessed after one or two
cycles of conventional chemotherapy repeated every 3–4 weeks,
and this duration was considered to correspond to four cycles of
our regimen, and (2) we felt that too much time was required to
complete an evaluation of toxicity for all cycles. The registration
period in this study was 2.5 years, 2.5 times longer than planned,
but the total duration of the pause in registration required to
evaluate DLT was not as long as expected. Second, the
recommended dose for phase II trials was defined in two ways
according to the protocol of the current study: the dose level prior
to MTD and the dose producing the highest dose intensity. The
doses determined by the two definitions were consistent in this
study, but they could differ for other chemotherapy combinations.
Which definition is preferable depends largely on how important it
is to increase the dose intensity of the chemotherapeutic regimen.
Third, this study required a large number of patients. The number
of patients required at each dose level to calculate the dose
intensity was 6–12, twice as many as a conventional phase I trial.
This method of calculation, however, would be sufficient at dose
levels close to the recommended dose. In addition, the starting
dose of irinotecan, which was determined to be 20mgm
2, might
have been too low. Standard criteria for the selection of a starting
dose in combination phase I studies have not been established.
This is the first study to combine the use of the topoisomerase I
inhibitor irinotecan and the topoisomerase II inhibitor etoposide
together with cisplatin. Topoisomerases are essential for the
maintenance of cellular viability throughout the cell cycle, and
alterations in the regulation of one topoisomerase are often
compensated for by alterations in the other. Preclinical studies
showed that cell lines with deficient topoisomerase I activity were
more sensitive to topoisomerase II inhibitors, and that cell lines
resistant to topoisomerase II inhibitors have increased sensitivity
to topoisomerase I inhibitors (Vasey and Kaye, 1997). In clinical
trials, however, concurrent or sequential administration of
irinotecan and etoposide resulted in severe toxicity and failed to
produce a superior antitumour activity than irinotecan alone in
patients with NSCLC (Ando et al, 1997; Oshita et al, 1997). In the
present trial, each agent was given separately for about 1 week. The
relatively mild toxic profile of this study may be partly attributable
to the separate administration of these two agents.
The response rates and their confidence intervals for SCLC and
NSCLC in this study exceeded the criteria required for a phase II
study. The median survival times of 11.9 and 10.1 months for
metastatic SCLC and NSCLC, respectively, were also promising,
although the number of patients with SCLC was too small to
evaluate survival. We are conducting two phase II studies, one in
patients with untreated extensive SCLC and the other in patients
with recurrent SCLC. We have not planned a phase II study for
NSCLC, because several new promising agents for this disease are
now available.
In conclusion, this is the first study to define a schedule for a
triplet combination of cisplatin, irinotecan and etoposide with a G-
CSF support. The recommended dose of irinotecan for further
studies is 90mgm
2 repeated every 2 weeks in combination with
weekly cisplatin and biweekly etoposide treatments. This treatment
regimen shows promising antitumour activity in patients with
stage IV SCLC and NSCLC.
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